Company intelligence / Profile preview

Jiangsu Kanion Pharmaceutical Co., Ltd.

Ownership: Private
Employees: ~5443
Development stage: Commercial

Overview

The company received registration for Yunujian Granules in April 2025. They have a diverse product portfolio with over 300 products across various therapeutic areas.

Therapeutic areas: OncologyWomen's HealthOtherCardiovascularInfectious Diseases
Modalities: Chinese medicinesmodern pharmaceuticalscapsulesoral liquidgranuleselectuarytabletspillspatchinjections
Industry: Biotech

Drug pipeline

21 assets

longxuetongluo

20 more assets in the full pipeline.

Partnerships

Entered European market in 2016 establishing partnerships with local distributorsPartnership with a European biotech company in 2023[9]

Beyond the preview

Go deeper on Jiangsu Kanion Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Kanion Pharmaceutical Co., Ltd..